Who Owns Vyndaqel?
Vyndaqel is owned by Pfizer Inc. (NYSE: PFE), a publicly traded American pharmaceutical company headquartered in New York City. Vyndaqel (tafamidis meglumine) and its single-capsule formulation Vyndamax (tafamidis) treat transthyretin amyloidosis. The drug was first approved in Europe in 2011 and received FDA approval for cardiomyopathy in May 2019.
Vyndaqel Timeline
GlobalOfficial Website
Who Owns Vyndaqel?
- Parent Company: Pfizer Inc.
- Ownership Type: Product line
- Acquisition Year: 2010
- Company Type: Publicly Traded
- Stock Ticker: NYSE: PFE
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Vyndaqel | Pfizer Inc. | Product line |
Where to Buy
Disclosure: We may earn commission from purchases
Vyndaqel on AmazonAdvertisement
History of Vyndaqel
- Founded: 2011
- Founders: FoldRx Pharmaceuticals (original development), Pfizer Inc. (development and commercialization)
- Acquired by Pfizer Inc.: 2010
Transthyretin amyloidosis is a disease in which the transthyretin protein misfolds and deposits as amyloid in nerves and heart tissue, producing progressive polyneuropathy and cardiomyopathy. For most of the twentieth century it was considered untreatable, with liver transplant the only option for the hereditary form.
Jeffery Kelly's research at Scripps demonstrated that small molecules could stabilize the transthyretin tetramer and prevent misfolding. FoldRx licensed the approach and developed tafamidis through the 2000s. Pfizer acquired FoldRx in 2010, taking the drug through regulatory submission and global commercialization.
The European Medicines Agency approved Vyndaqel in 2011 for transthyretin polyneuropathy, the first drug ever approved for the disease. The FDA initially declined approval for the neuropathy indication in 2012, requesting additional data, and the drug's US path stalled for years.
The ATTR-ACT cardiomyopathy trial changed the trajectory. Published in 2018, it demonstrated reduced mortality and cardiovascular hospitalizations in transthyretin cardiomyopathy, a larger and previously unrecognized patient population. The FDA approved Vyndaqel and Vyndamax for the cardiomyopathy indication in May 2019, and the franchise became a blockbuster almost immediately, generating over $5 billion annually as diagnosis rates climbed with awareness campaigns and improved cardiac imaging.
Advertisement
Competition arrived from RNA-silencing therapies including Alnylam's Onpattro and Amvuttra, which attack the disease by reducing transthyretin production rather than stabilizing it, and from BridgeBio's acoramidis, approved in 2024 as a competing stabilizer. Vyndaqel retained first-mover share into FY2025 despite the entrants.
About Pfizer Inc.
What does Pfizer own?
Pfizer owns a portfolio of prescription medicines and vaccines spanning oncology, cardiovascular, immunology, vaccines, and rare diseases. Key products include Eliquis (anticoagulant), Prevnar (pneumococcal vaccine), Ibrance (breast cancer), Vyndaqel (rare heart disease), Paxlovid (COVID-19 antiviral), Comirnaty (COVID-19 vaccine, with BioNTech), and Abrysvo (RSV vaccine). The 2023 acquisition of Seagen added oncology antibody-drug conjugates including Padcev, Adcetris, and Tukysa. The 2025 acquisition of Metsera added obesity treatment candidates to the pipeline.
Is Pfizer publicly traded?
Yes, Pfizer Inc. is listed on the New York Stock Exchange under ticker PFE. The company has been publicly traded since 1944. Pfizer has no single controlling shareholder, with major institutional holders including Vanguard Group, BlackRock, and State Street. Pfizer is a component of the Dow Jones Industrial Average and the S&P 500.
Who founded Pfizer?
Pfizer was founded in 1849 in Brooklyn, New York by Charles Pfizer and his cousin Charles Erhart. Charles Pfizer was a German-born chemist who emigrated to the United States. The company's first product was santonin, an antiparasitic agent. Pfizer's breakthrough into modern pharmaceuticals came during World War II when the company developed large-scale penicillin production using deep-tank fermentation.
Advertisement
Where is Pfizer headquartered?
Pfizer is headquartered in New York City, New York, USA. The company maintains its principal executive offices in Midtown Manhattan. Pfizer operates manufacturing facilities in the United States, Belgium, Ireland, the United Kingdom, Germany, Japan, China, India, and Brazil, and sells products in more than 125 countries worldwide.
How many products does Pfizer sell?
Pfizer sells dozens of prescription medicines and vaccines across multiple therapeutic areas. The company's portfolio includes products in oncology, vaccines, cardiovascular, immunology, rare diseases, and hospital products. Several of Pfizer's products each generate over $1 billion in annual revenue, including Eliquis, Prevnar, Ibrance, and Vyndaqel. The company's research pipeline includes hundreds of compounds in various stages of clinical development.
Who owns Pfizer?
Pfizer Inc. is publicly traded on the NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. Major institutional shareholders include Vanguard Group, BlackRock, and State Street. Albert Bourla serves as Chairman and CEO. Pfizer has no founding family or private equity controlling shareholder.
What is Pfizer's financial performance?
For full-year 2025, Pfizer reported revenue of $62.6 billion, a 2% decrease from $63.6 billion in FY2024. Excluding COVID-19 products (Comirnaty and Paxlovid), revenue grew 6% operationally. Net income was $7.77 billion, down 3% from $8.03 billion. Adjusted diluted EPS was $3.22, up 4% from $3.11. Net cash from operations was $11.7 billion. For FY2026, Pfizer projects revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00.
Advertisement
- Founded: 1849
- Headquarters: New York, New York, USA
- Company Type: Publicly Traded
- Stock: NYSE: PFE
- Revenue: $62.6 billion (FY2025)
- Employees: approximately 88,000
Where Is Vyndaqel Made / Based?
- Headquarters: New York, New York, USA
- Manufacturing / Operations: United States, Ireland
Vyndaqel Categories & Tags
Vyndaqel Recalls & Controversies
Vyndaqel's principal controversy is price. The drug carries a US list price exceeding $200,000 per year, making it one of the most expensive cardiovascular therapies ever sold, and it has featured prominently in drug-pricing debates and congressional inquiries into orphan drug economics. Pfizer defends the price against the drug's orphan designation economics and its mortality benefit, while patient advocates have cited the cost as an access barrier.
Pfizer settled litigation and faced criticism over its practice of offering the drug at discounted or free supply outside the United States while list pricing in the US was substantially higher, a common structure in orphan drug pricing that drew scrutiny.
The drug's safety profile is comparatively clean, with labeling focused on limited adverse events consistent with a disease-stabilization therapy.
Advertisement
Brands Owned by Pfizer Inc.
Healthcare PharmaceuticalsAbrysvo
Owned by Pfizer Inc.
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
rsv-vaccinevaccinesmaternal-immunization
Healthcare PharmaceuticalsAdcetris
Owned by Pfizer Inc.
Prescription antibody-drug conjugate treatment for classical Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphomas, co-developed by Seagen and licensed to Takeda Pharmaceutical.
oncologyantibody-drug-conjugatelymphoma
Healthcare PharmaceuticalsCaduet
Owned by Pfizer Inc.
Prescription combination drug containing amlodipine and atorvastatin, co-promoted by Pfizer and developed for simultaneous blood pressure and cholesterol management.
prescription-drugcardiovascularhypertension
Healthcare PharmaceuticalsChantix
Owned by Pfizer Inc.
Prescription smoking cessation medication (varenicline) developed by Pfizer, FDA-approved in 2006.
smoking-cessationvareniclinenicotinic-receptor
Healthcare PharmaceuticalsComirnaty
Owned by Pfizer Inc.
Pfizer-BioNTech COVID-19 mRNA vaccine, the first FDA-approved COVID vaccine in the United States, co-commercialized globally by Pfizer and BioNTech.
covid-19mrna-vaccinevaccines
Healthcare PharmaceuticalsDiflucan
Owned by Pfizer Inc.
Prescription antifungal medication (fluconazole) for treating candidiasis, cryptococcal meningitis, and other fungal infections. Developed by Pfizer, FDA-approved in 1990.
antifungalfungal-infectioncandidiasis
Vyndaqel Ownership: Pros & Cons
Advantages
- +Wholly owned by Pfizer, acquired through a modest biotech deal that became a blockbuster
- +First-mover position in a category still defined by underdiagnosis, leaving room for expansion
- +Mortality benefit data provides strong clinical differentiation for prescribers
- +Orphan drug status provides exclusivity periods and pricing protection
Considerations
- -List price exceeding $200,000 annually attracts sustained affordability criticism
- -Direct competitors Alnylam and BridgeBio now offer approved alternatives
- -Revenue depends on continued expansion of diagnosis rates rather than share gains alone
- -Medicare price negotiation and orphan drug policy scrutiny are longer-term risks
Advertisement
Frequently Asked Questions About Vyndaqel
Sources & Further Reading
Advertisement
Competitors to Vyndaqel
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals | USA | 2019 | Mass market | Global | All-ages |
Competitive Analysis
Market Positioning: Vyndaqel competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to Vyndaqel
Looking for brands with different ownership structures? These similar brands are not owned by Pfizer Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsAvaility
Owned by Availity
The largest real-time health information network in the US, owned by a consortium of major health insurers and Novo Holdings.
healthcare-technologyclearinghouseclaims-processing
Privately Owned
Availity is privately owned, unlike Vyndaqel which is under a publicly traded parent company.
Healthcare PharmaceuticalsBand-Aid
Owned by Kenvue
American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid is the leading adhesive bandage brand in the United States and is sold in more than 100 countries.
wound-careadhesive-bandagefirst-aid
Privately Owned
Band-Aid is privately owned, unlike Vyndaqel which is under a publicly traded parent company.
Healthcare PharmaceuticalsBenadryl
Owned by Kenvue
American brand of antihistamine medication used to treat allergies, itching, and cold symptoms, manufactured and marketed by Johnson & Johnson.
antihistamineallergy-reliefcold-medicine
Privately Owned
Benadryl is privately owned, unlike Vyndaqel which is under a publicly traded parent company.
Healthcare PharmaceuticalsBoots
Owned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
pharmacyhealth-beautyuk-retail
Privately Owned
Boots is privately owned, unlike Vyndaqel which is under a publicly traded parent company.
Healthcare PharmaceuticalsDuane Reade
Owned by Walgreens Boots Alliance
Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.
pharmacydrugstorenew-york
Privately Owned
Duane Reade is privately owned, unlike Vyndaqel which is under a publicly traded parent company.
Healthcare PharmaceuticalsMD Clarity
Owned by MD Clarity
Seattle healthcare SaaS platform for patient cost estimates, payer contract management, and underpayment detection.
healthcare-technologyrevenue-cyclecontract-management
Privately Owned
MD Clarity is privately owned, unlike Vyndaqel which is under a publicly traded parent company.
Pfizer Inc. Stock Information
Advertisement
Jobs at Pfizer Inc.
Latest News About Vyndaqel
Advertisement
Related Articles About Vyndaqel
View more articles
Industry Analysis
Brands That Relocated Headquarters for Tax Reasons
From Pfizer's failed Irish inversion to ExxonMobil's Texas move, discover why brands relocate their headquarters for tax and legal reasons — and how it affects their brand portfolios. Explore our database.
Who Brands StaffMay 22, 2026
TaxHeadquartersCorporate Relocation
Industry Analysis
How Government Policy Shapes Brand Ownership
From antitrust rulings to tariff wars, government policy determines which brands get acquired, which get blocked, and which stay independent. Our guide explains how policy shapes brand ownership. Explore our database.
Who Brands StaffMay 17, 2026
GovernmentPolicyAntitrust
Brand Comparisons
Pfizer vs Johnson & Johnson: Pharma Brand Portfolios Compared
Pfizer and Johnson & Johnson are two of the most recognizable names in healthcare. But their brand portfolios look nothing alike. Here is a complete breakdown of what each company owns, how they got there, and what sets them apart.
Who Brands StaffMar 16, 2026
PharmaceuticalPfizerJohnson And Johnson
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization
Brandspecialty-pharmacy
Accredo
Specialty pharmacy founded in 1996 in Memphis, serving patients with complex and rare conditions as the specialty pharmacy of Evernorth within The Cigna Group.
Brand in Healthcare & Pharmaceuticals
rare-diseaseevernorth